



0300
#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: FREDEKING *et al.*
Serial No.: 10/038,557
Filed: January 3, 2002


For: *COMPOSITIONS AND METHODS
FOR TREATING HEMORRHAGIC
VIRUS INFECTIONS AND OTHER
DISORDERS*

Art Unit: Unassigned
Examiner: Unassigned

CERTIFICATE OF MAILING BY "EXPRESS
MAIL"
"Express Mail" Mailing Label Number
EL 870639273 US
Date of Deposit June 5, 2002

I hereby certify that this paper is being
deposited with the United States Postal
"Express Mail Post Office to Addressee"
Service under 37 C.F.R. §1.10 on the date
indicated above and addressed to:

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202


Kelly Fischer

TRANSMITTAL LETTER

Commissioner for Patents
Arlington, VA 22202

Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, Form PTO-1449 (1 page), and references for filing in connection with the above-identified application. Because this Information Disclosure Statement is filed prior to receipt of a First Office Action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 50-1213, as stated below:

- ☒ The Commissioner is hereby authorized to charge any fee, including any submitted herewith if the attached check(s) is in the wrong amount or otherwise improper or missing, that may be due in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,
HELLER EHRMAN WHITE & McAULIFFE LLP

By:


Stephanie Seidman
Registration No. 33,779

Attorney Docket No. 24881-301D
Address all correspondence to:
Stephanie Seidman, Esq.
HELLER EHRMAN WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, 7th Floor
San Diego, California 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
E-mail: sseidman@HEWM.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: FREDEKING *et al.*
Serial No.: 10/038,557
Filed: January 3, 2002

For: *COMPOSITIONS AND METHODS FOR
TREATING HEMORRHAGIC VIRUS
INFECTIONS AND OTHER DISORDERS*


Art Unit: Unassigned
Examiner: Unassigned

CERTIFICATE OF MAILING BY "EXPRESS
MAIL"

"Express Mail" Mailing Label Number
EL 870639273 US
Date of Deposit June 5, 2002

I hereby certify that this paper is being
deposited with the United States Postal
"Express Mail Post Office to Addressee"
Service under 37 C.F.R. §1.10 on the date
indicated above and addressed to:

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202


Kelly Fischer

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE
WITH 37 C.F.R. §§ 1.97-1.98**

Commissioner for Patents
Arlington, VA 22202

Dear Sir:

Since this Supplemental Information Disclosure Statement is filed before the receipt of a first Office Action on the merits for the above-captioned application, no filing fee is due. If it is determined that a fee is due, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Form PTO-1449 (1 page) is provided herewith.

The documents listed on the Form PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

U.S.S.N. 10/038,557

FREDEKING *et al.*

Supplemental Information Disclosure Statement

Applicant respectfully requests that the Examiner review the foregoing references and information and that they be made of record in the file history of the above-captioned application.

Respectfully submitted,
HELLER EHRMAN WHITE & McAULIFFE LLP

By:


Stephanie Seidman
Registration No. 33,779

Attorney Docket No. 24881-301D

Address all correspondence to:

Stephanie Seidman, Esq.

HELLER EHRMAN WHITE & McAULIFFE LLP

4350 La Jolla Village Drive, 7th Floor

San Diego, California 92122-1246

Telephone: (858) 450-8400


Facsimile: (858) 587-5360

E-mail: sseidman@HEWM.com

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
	APPLICANT FREDEKING <i>et al.</i>	
	FILING DATE January 3, 2002	GROUP 1646

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

* Copies of articles not enclosed.



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
None							

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No
None							

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AA	Conti <i>et al.</i> , "MCP-1 and RANTES Are Mediators of Acute and Chronic Inflammation", <i>Allergy and Asthma Proc.</i> , <u>22</u> (3):133-137 (2001)
	AB	Piet <i>et al.</i> , "The Use of Tri(n-butyl)phosphate Detergent Mixtures to Inactivate Hepatitis Viruses and Human Immunodeficiency Virus in Plasma and Plasma's Subsequent Fractionation", <i>Transfusion</i> , <u>30</u> (7):591-598 (1990)
	AC	van Deuren, M., "Kinetics of Tumour Necrosis Factor-Alpha, Soluble Tumour Necrosis Factor Receptors, Interleukin 1-Beta and its Receptor Antagonist During Serious Infections", <i>Eur. J. Clin. Microbiol. Infect. Dis.</i> <u>13</u> (Supp. 1):12-16 (1994)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**